Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Gross Profit: 2018-2023

Historic Gross Profit for Denali Therapeutics (DNLI) over the last 6 years, with Dec 2023 value amounting to $330.5 million.

  • Denali Therapeutics' Gross Profit fell 64.40% to $1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $340.8 million, marking a year-over-year increase of 207.89%. This contributed to the annual value of $330.5 million for FY2023, which is 204.74% up from last year.
  • Per Denali Therapeutics' latest filing, its Gross Profit stood at $330.5 million for FY2023, which was up 204.74% from $108.5 million recorded in FY2022.
  • Denali Therapeutics' 5-year Gross Profit high stood at $335.7 million for FY2020, and its period low was $26.7 million during FY2019.
  • For the 3-year period, Denali Therapeutics' Gross Profit averaged around $162.6 million, with its median value being $108.5 million (2022).
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 1,158.19% in 2020, then slumped by 85.50% in 2021.
  • Over the past 5 years, Denali Therapeutics' Gross Profit (Yearly) stood at $26.7 million in 2019, then spiked by 1,158.19% to $335.7 million in 2020, then crashed by 85.50% to $48.7 million in 2021, then skyrocketed by 122.90% to $108.5 million in 2022, then soared by 204.74% to $330.5 million in 2023.